Cargando…
Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169264/ https://www.ncbi.nlm.nih.gov/pubmed/37179718 http://dx.doi.org/10.31662/jmaj.2022-0165 |
_version_ | 1785039019144380416 |
---|---|
author | Saito, Hirokazu Kadono, Yoshihiro Shono, Takashi Kamikawa, Kentaro Urata, Atsushi Nasu, Jiro Uehara, Masayoshi Matsushita, Ikuo Kakuma, Tatsuyuki Tada, Shuji |
author_facet | Saito, Hirokazu Kadono, Yoshihiro Shono, Takashi Kamikawa, Kentaro Urata, Atsushi Nasu, Jiro Uehara, Masayoshi Matsushita, Ikuo Kakuma, Tatsuyuki Tada, Shuji |
author_sort | Saito, Hirokazu |
collection | PubMed |
description | INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A) and previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS, including obstructive jaundice or acute cholangitis (group B). In this study, we aimed to examine PEP risk in group B by comparing PEP risks between groups A, B, and currently symptomatic patients (group C). METHODS: In this multicenter retrospective study, we examined 77 patients in group A, 41 patients in group B, and 1225 patients in group C who had native papillae. PEP incidence rates between asymptomatic patients at the time of ERCP (groups A and B) and symptomatic patients (group C) were compared using one-to-one propensity score matching. Bonferroni’s correction analysis was also performed to compare PEP incidence rates among the three groups. RESULTS: As per our findings, PEP incidence rate in propensity score-matched groups A and B was significantly higher than that of propensity score-matched group C (13.2% [15/114] versus 4.4% [5/114], respectively, P = 0.033). In groups A and B, PEP incidence rates were 11.7% (9/77) and 14.6% (6/41), respectively. PEP risk in group B was similar to that in group A (P = 1.0). PEP incidence in group B was significantly higher than PEP incidence in group C (14.6% (6/41)) vs. 2.9% (35/1225)) (P = 0.005)). CONCLUSIONS: ERCP for previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS may increase the risk of PEP compared with ERCP for currently symptomatic patients. Thus, ERCP should be performed before patients become asymptomatic using conservative treatments if patients can tolerate ERCP procedures. |
format | Online Article Text |
id | pubmed-10169264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Japan Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-101692642023-05-10 Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones Saito, Hirokazu Kadono, Yoshihiro Shono, Takashi Kamikawa, Kentaro Urata, Atsushi Nasu, Jiro Uehara, Masayoshi Matsushita, Ikuo Kakuma, Tatsuyuki Tada, Shuji JMA J Original Research Article INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A) and previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS, including obstructive jaundice or acute cholangitis (group B). In this study, we aimed to examine PEP risk in group B by comparing PEP risks between groups A, B, and currently symptomatic patients (group C). METHODS: In this multicenter retrospective study, we examined 77 patients in group A, 41 patients in group B, and 1225 patients in group C who had native papillae. PEP incidence rates between asymptomatic patients at the time of ERCP (groups A and B) and symptomatic patients (group C) were compared using one-to-one propensity score matching. Bonferroni’s correction analysis was also performed to compare PEP incidence rates among the three groups. RESULTS: As per our findings, PEP incidence rate in propensity score-matched groups A and B was significantly higher than that of propensity score-matched group C (13.2% [15/114] versus 4.4% [5/114], respectively, P = 0.033). In groups A and B, PEP incidence rates were 11.7% (9/77) and 14.6% (6/41), respectively. PEP risk in group B was similar to that in group A (P = 1.0). PEP incidence in group B was significantly higher than PEP incidence in group C (14.6% (6/41)) vs. 2.9% (35/1225)) (P = 0.005)). CONCLUSIONS: ERCP for previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS may increase the risk of PEP compared with ERCP for currently symptomatic patients. Thus, ERCP should be performed before patients become asymptomatic using conservative treatments if patients can tolerate ERCP procedures. Japan Medical Association 2023-03-13 2023-04-14 /pmc/articles/PMC10169264/ /pubmed/37179718 http://dx.doi.org/10.31662/jmaj.2022-0165 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Original Research Article Saito, Hirokazu Kadono, Yoshihiro Shono, Takashi Kamikawa, Kentaro Urata, Atsushi Nasu, Jiro Uehara, Masayoshi Matsushita, Ikuo Kakuma, Tatsuyuki Tada, Shuji Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title | Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title_full | Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title_fullStr | Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title_full_unstemmed | Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title_short | Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones |
title_sort | post-endoscopic retrograde cholangiopancreatography pancreatitis after conservative treatment for symptomatic bile duct stones |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169264/ https://www.ncbi.nlm.nih.gov/pubmed/37179718 http://dx.doi.org/10.31662/jmaj.2022-0165 |
work_keys_str_mv | AT saitohirokazu postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT kadonoyoshihiro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT shonotakashi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT kamikawakentaro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT urataatsushi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT nasujiro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT ueharamasayoshi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT matsushitaikuo postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT kakumatatsuyuki postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones AT tadashuji postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones |